We sought to evaluate the effects of mechanical thrombectomy on myocardial reperfusion during direct angioplasty for acute myocardial infarction (AMI). BACKGROUND Embolization of thrombus and plaque debris may occur during direct angioplasty for AMI.
At present, for most patients with acute myocardial infarction (AMI), direct percutaneous coronary angioplasty (PTCA) is the best reperfusion strategy (1) . This strategy, particularly when using coronary stents, has been shown to increase patency of the infarct-related artery (IRA) (2, 3) . However, a discrepancy between vessel patency and rescue of jeopardized myocardium after pharmacologic or interventional treatment of AMI has been documented in up to
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one-third of patients (4 -8) . This condition may be multifactorial and reflects damage to microvascular integrity, established both during ischemia and at the time of reperfusion. Possible related factors include damage to endothelial cells; tissue edema (9, 10) ; release of vasoconstrictive and inflammatory mediators; intravascular plugging of leukocytes (11, 12) , platelets, and fibrin aggregates (13) . Moreover, embolization of plaque and thrombus debris, either spontaneous or induced by percutaneous intervention, may lead to obstruction in distal coronary arterioles, limiting the efficacy and the extent of myocardial reperfusion (14) . New mechanical devices to remove thrombus or to prevent embolization of thrombus and plaque during percutaneous coronary interventions have become available (15) (16) (17) , but little is known regarding the effects on myocardial reperfusion during direct angioplasty (18) .
The present randomized study was designed to evaluate the effects of mechanical thrombus removal on myocardial reperfusion in patients undergoing direct angioplasty for AMI.
METHODS

Patient population. Between August 2000 and October 2001
, 92 patients undergoing direct PTCA within 12 h from onset of AMI were enrolled in the study.
Inclusion criteria were continuous chest pain for at least 30 min and within 12 h of onset of pain, and ST-segment elevation Ն1 mm (0.1 mV) in two or more contiguous leads on the 12-lead electrocardiogram (ECG) (ST-segment depression in the right precordial leads V 1 to V 4 was considered a sign of transmural ischemia of the posterior myocardial wall), angiographic evidence of intraluminal thrombus in the IRA, Thrombolysis In Myocardial Infarction (TIMI) flow Յ2, and/or Ն70% diameter stenosis (DS).
Exclusion criteria were presence of left bundle-branch block or pacemaker-induced rhythm at admission ECG, left main stem lesions, IRA diameter Ͻ2.5 mm.
Patients older than 75 years and patients in cardiogenic shock were not excluded from the study. After providing informed consent, patients fulfilling the inclusion criteria were 1:1 randomly assigned to a strategy of intracoronary thrombectomy followed by stenting, or to a conventional strategy of stenting alone. Procedure and device description. Thrombectomy was performed using the X-Sizer catheter system (ev-3, White Bear Lake, Minnesota). The device is a two-lumen overthe-wire system (available diameters 1.5, 2.0, and 2.3 mm) with a helical shape cutter at its distal tip. The cutter rotates at 2,100 rpm driven by a hand-held battery motor unit. One catheter lumen is connected to a 250-ml vacuum bottle, and aspirated debris is collected in an in-line filter. Two or three passages across the lesion from proximal to distal were performed by slowly advancing the activated catheter. Subsequently, additional balloon angioplasty and/or coronary stenting was performed (Fig. 1) . Before the intervention all patients received aspirin. Heparin (70 U/kg) was given to maintain the activated clotting time Ͼ250 s. Glycoprotein IIb/IIIa inhibitors were used according to the judgment of the operator. Angiographic analysis. The coronary angiograms were performed using digital technique (Integris 3000, Philips Medical Systems, Best, the Netherlands). Intracoronary thrombus was angiographically identified and scored in five degrees as previously described by Gibson et al. (19) . Patients were enrolled if TIMI thrombus score was Ն2. Thrombus score, TIMI flow grade (20) , and myocardial blush grade (MBG) as described by van't Hof et al. (8) after guidewire positioning, after thrombectomy, and at the end of the procedure were determined off-line by two experienced operators blinded to clinical data. Quantitative coronary analysis was performed using the Coronary Quantification Package (Philips Medical Systems, Eindhoven, The Netherlands). Technical success of thrombectomy was defined as the ability of the device to cross the target lesion and to increase TIMI flow by Ն1 and/or to reduce TIMI thrombus score by Ն1. Procedural success of the intervention was defined by the achievement of TIMI 3 flow grade and a residual stenosis Ͻ20%. Electrocardiographic analysis. In each patient a 12-lead ECG was recorded at admission and 60 min after the procedure. The sum of ST-segment elevation was assessed at 20 ms from J-point in the leads V 1 to V 6 , I, and aVL for anterior infarction and in the leads II, III, aVF, V 5 , V 6 for nonanterior infarction; in the latter the ST-segment depression in leads V 1 to V 4 was also analyzed, as a sign of transmural ischemia of the posterior wall. The two ECGs were compared, and the ST-segment elevation was classified as normalized if there was no residual ST-segment elevation after the procedure, improved if a regression Ն50% was observed, unchanged if the ST-segment elevation sum appeared unchanged, worsened or regressed Ͻ50% (21). Echocardiogaphic analysis. All patients underwent twodimensional-transthoracic echocardiographic examination (Sonos 5500 Hewlett-Packard, Andover, Massachusetts) at admission, at discharge, and at 30-day follow-up. Left ventricular ejection fraction was calculated using the arealength method in the apical four-chamber view and the apical two-chamber view (22) . All measures were given as mean value of two views. Enzymatic infarct size. Infarct size was estimated by measurement of enzyme activity by using total creatine kinase (CK) and band fraction MB as reference enzymes. The enzymatic activity was reported as unit of activity per liter, and was assessed every 6 h in the first 48 h after admission, and then twice daily up to discharge. Peak value release from eight serial measurements up to 48 h after admission was reported. Histopathological analysis. In 24 of 46 (52.2%) patients undergoing thrombectomy, histopathologic analysis was performed on debris collected in the filter by light microscopy after staining with hematoxylin-eosin and Azan-Mallory. Study end points. The primary end point of this study was the occurrence of postprocedural MBG-3. Secondary end points included ST-segment regression Ն50%, enzymatic infarct size, left ventricular ejection fraction at discharge, and in-hospital occurrence of heart failure. In-hospital and 30-day occurrence of adverse events including death, nonfatal reinfarction, stroke, and major bleedings were also collected. Follow-up. At 30 days after the procedure, the patients underwent clinical and echocardiographic evaluation. Statistical analysis. The number of patients included in the study was based on the estimation of the sample size needed to identify a significant difference in the primary end point. In a pilot study on thrombectomy in patients with acute myocardial infarction, we found a rate of 60% in postprocedural MBG-3 (23) . Assuming that the rate of MBG-3 is around 30% in patients treated with standard approach direct PTCA (8,24), we estimated that 45 patients would be required in each group for the study to have a power of 80% to detect an absolute difference in the occurrence of MBG-3 of 30% with a two-sided alpha value of 0.05. All analyses were performed according to intentionto-treat principle. Categorical variables are presented as frequency values and were compared by Fisher exact test and chi-square. The Fisher exact test was used when the expected event had a low frequency, particularly when at least one cell in 2-2 table had a value Ͻ5; otherwise the chi-square test was used. Continuous variables are expressed as mean Ϯ SD, and were compared by Student t test or analysis of variance (ANOVA) for normally distributed variables, and by Wilcoxon rank-sum test for not normally distributed variables. Repeated measures of continuous variables of each group were analyzed by repeated measures ANOVA with Bonferroni correction for multiple comparisons. Multivariate regression analysis was performed to identify independent predictors of MBG-3 after the procedure. This model included age Ͼ65 years, infarct location, diabetes, Killip class Ն2, ischemic time, previous myocardial infarction, blood pressure Ͻ100 mm Hg, heart ratio Ͼ100 beats/min, multivessel disease, occluded IRA at baseline, the presence of collaterals, use of glycoprotein IIb/IIIa inhibitors, and thrombectomy. A p value Ͻ0.05 was interpreted as statistically significant. Statistical analysis was performed using SPSS 11.0 (SPSS Inc., Chicago, Illinois).
RESULTS
Ninety-two patients meeting the inclusion criteria were enrolled. Forty-six patients were randomly assigned to undergo thrombectomy, and 46 to conventional percutaneous coronary interventions. There were no significant differences in baseline clinical and angiographic characteristics between groups (Tables 1 and 2) . Procedural data and angiographic analysis. Procedural angiographic results are reported in Figure 2 and Table 2 . The postprocedural TIMI flow was similar between patients undergoing thrombectomy and patients treated conventionally (p ϭ 0.39). Postprocedural DS, minimal lumen diameter, and reference vessel diameter were not different between groups. The procedural success, as previously defined, was reached in 43 of 46 (93.5%) patients undergoing thrombectomy and in 44 of 46 (95.6%) patients assigned to conventional treatment (p ϭ 0.43). Angiographic no-reflow and distal embolization tended to occur less commonly in patients randomized to thrombectomy (Table 2 ). Side branch occlusion was similar in both groups, and coronary perforation was not observed.
The rate of patients treated with stent implantation was similar in both groups. Likewise, the number of stents per patient, the mean stented segment length, and the stent/ vessel ratio, as well as the maximum pressure of balloon inflation was not statistically different between groups. Stent implantation without balloon predilation was performed more often in patients undergoing thrombectomy (p ϭ 0.003). The administration of glycoprotein IIb/IIIa inhibi- (Fig. 4) . By multivariate analysis, thrombectomy was an independent predictor of postprocedural MBG-3 (odds ratio, 3.27; 95% confidence interval, 1.06 to 10.05; p ϭ 0.02). Assessing the reperfusion according to ECG criteria, postprocedural ST-segment elevation regressed Ն50% in a significantly higher percentage of patients treated with thrombectomy (82.6% vs. 52.2%; p ϭ 0.001) ( Table 3) . Infarct size and left ventricular function. The CK and CK-MB peak release and left ventricular ejection fraction at baseline, discharge, and at 30 days were not significantly different between groups (Table 3 ). Regardless of treatment There were no differences between groups in TIMI flow at baseline, after wiring, and at the end of procedure (A). The MBG was similar between groups at baseline and after wire crossing. At the end of procedure, the MBG was significantly higher (p ϭ 0.006; chi-square) in patients undergoing thrombectomy (B). 
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Clinical outcomes. The in-hospital occurrence of death, reinfarction, and severe bleeding were not statistically different between groups (Table 3 ). In the thrombectomy group, three patients died during hospitalization, two with refractory cardiogenic shock, and one because of refractory ventricular fibrillation. In the control group, three patients died during hospitalization, two with cardiogenic shock, and one after massive retroperitoneal bleeding. Reinfarction occurred in one patient assigned to thrombectomy because of stent thrombosis, and in one patient assigned to conventional strategy because of non-IRA occlusion. In-hospital congestive heart failure occurred more often in patients assigned to conventional strategy, but this difference was not statistically significant (21.7% vs. 10.9%, p ϭ 0.17). Regardless of the treatment strategy, patients with postprocedural MBG 0/1/2 experienced in-hospital heart failure more frequently than patients with postprocedural MBG-3 (14/42 vs. 1/50, p ϭ 0.0001). At 30-day follow-up there was no difference in major adverse clinical events between groups (Table 3) .
DISCUSSION
Thrombus removal and myocardial reperfusion. The goal of direct angioplasty for the treatment of AMI is not only the restoration of normal epicardial flow, but also achievement of optimal myocardial tissue reperfusion (4).
Myocardial reperfusion can be assessed using angiographic (8) and electrocardiographic (21, 25) parameters. Thrombus and plaque debris embolization is one of the mechanisms affecting the microvasculature at the time of reperfusion by mechanical capillary obstruction leading to endothelium dysfunction (26) , and by inflammation of the myocardium (27) . Using an experimental canine model, Dörge et al. (27) studied the effects of coronary microembolization on the extent of myocardial inflammation and necrosis showing that the injection of inert microspheres in the microvascular coronary circulation of the canine heart led to a similar amount of myocardial necrosis and systolic dysfunction and a more pronounced inflammatory response compared with an epicardial coronary occlusion model.
In the present randomized study, patients undergoing thrombectomy showed similar postprocedure epicardial flow but improved myocardial reperfusion documented by significantly improved myocardial blush and ST-segment resolution, compared with patients treated conventionally. It appears that effective removal of thrombotic material at the lesion site improves myocardial reperfusion by reducing distal embolization occurring during plaque manipulation with balloon and stent.
Further evidence of effective thrombus removal is given by the significant angiographic reduction in thrombus bur- den after thrombectomy and by the presence of thrombotic debris in the aspirate in a high percentage of cases. Myocardial damage and left ventricular function. In previous studies, myocardial blush has been related to infarct size, left ventricular function (28) , and long-term mortality after AMI (8, 24) . In our study, patients treated with thrombectomy, despite the enhanced myocardial blush, did not show a significantly smaller myocardial damage assessed by total CK and CK-MB peak release. We observed a slight, but not significant, improvement of left ventricular function and in the occurrence of in-hospital congestive heart failure. The main explanation for this is probably that our study was not powered to demonstrate benefits in myocardial salvage and in ventricular function, but to assess surrogate markers known to be associated with these. Interestingly, patients with blush-3, regardless of the modality of treatment, showed a significant reduction in myocardial damage and a better ventricular function compared with patients with blush 0/1/2. This underlines the importance of achieving MBG-3 and supports the validity of MBG as surrogate end point in AMI studies.
Comparison with other studies. In the present study, the rate of myocardial blush-3 (71.7%) and ST-resolution Ն50% (82.6%) after adjunct thrombectomy was high compared with results of conventional balloon angioplasty and stent reported by van't Hof and by Stone (8,24) (MBG-3, 19% and 28%, respectively) and Claeys (25) (ST-resolution Ն50%: 64%). Recently, Beran and colleagues (18) reported on a randomized trial of thrombectomy versus conventional treatment including 49 patients with ST-elevation AMI. They showed a significantly improved ST-resolution but no difference in myocardial blush and coronary flow reserve after adjunctive intracoronary thrombectomy with the X-Sizer catheter. A possible explanation for the lack of benefit of thrombectomy on myocardial blush and coronary flow reserve is that in the cited study both parameters were evaluated in ST-and non-ST-elevation myocardial infarction. The EndiCor X-SIZER AMI registry (29) showed a high MBG-3 grade of 62% similar to our findings.
Other mechanical approaches to reduce embolization of thrombus during direct PTCA have been used successfully. They include rheolytic thrombectomy (15) , thrombus aspiration devices (30) , and distal protection devices (31) . Data from randomized studies on the effects of these devices on myocardial reperfusion during direct PTCA have not been reported.
Several pharmacologic approaches to improve myocardial reperfusion during direct angioplasty have been performed. Intracoronary adenosine and verapamil (32, 33) is administered to reduce the reperfusion injury but does not address the reduction of intracoronary thrombus burden. Glycoprotein IIb/IIIa receptor inhibitors in patients undergoing direct PTCA has been shown to improve microvascular function by limiting the effects of embolized thrombus and platelets, and by reducing the inflammatory response of the coronary microvasculature, as assessed by coronary flow velocity (34) . Associated therapy of IIb/IIIa inhibitors and thrombolytic therapy did show a 59% rate of complete ST-segment resolution (35) . In the present study, mechanical thrombectomy aiming to avoid distal embolization achieved similar good results as aggressive pharmacologic treatment aiming to reduce the consequences of distal embolization (32, 33) . It is unlikely that the results of the study were affected by the use of glycoprotein IIb/IIIa inhibitors, as reflected by the similar, relatively low, rate of abciximab administration in both groups (43.4% in thrombectomy arm and 41.3% in conventional arm). In a large randomized trial (36) , the use of abciximab as an adjunct to direct PTCA did not enhance ST-segment resolution or improve myocardial recovery at seven months. Also, in the X-SIZER AMI registry, the use of glycoprotein IIb/IIIa inhibitors did not show an additional benefit on myocardial reperfusion in patients treated with thrombectomy (37) . These data underline the importance of mechanical adjuncts to improve the procedural outcome of direct PTCA. Study limitations. The study reflects a single-center experience in a limited number of patients, and represents a mechanical attempt to optimize myocardial reperfusion in patients undergoing direct PTCA. Apart from considerations on the safety of the X-Sizer thrombectomy device and on its effect on myocardial reperfusion, any conclusions about the clinical efficacy of intracoronary thrombectomy cannot be drawn.
The study was limited to thrombus-containing lesions in relatively large coronary arteries and did not include the entire AMI population. Another limitation of the study is that the possible treatment benefit of adjunct pharmacologic therapy was not evaluated. Myocardial reperfusion represents such a wide and complex scenario, that synergistic mechanical and pharmacologic strategies to preserve microvascular integrity will be needed. Conclusions. Intracoronary thrombectomy with the X-Sizer catheter during catheter-based treatment of AMI improved myocardial reperfusion as assessed by myocardial blush and ST-segment resolution. Larger clinical trials are warranted to address the impact of thrombectomy on infarct size as well as on clinical outcome.
